Tuesday, June 14, 2022
7:00PM – 8:30PM ET
Please note this virtual program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.
- 1.5 CME Credits
- Create your own Personalized Poster
- Interactive, case-based learning environment
Oncology nurses are in an inherently valuable position to be in the frontline for treatment of HER2-positive solid tumors. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. For additional resources, please visit www.oncologynurse-ce.com
|Vamsidhar Velcheti, MD, FACP, FCCP
Director of Thoracic Medical Oncology
Perlmutter Cancer Center
Professor of Medicine
New York, NY
|Evelyn Robles-Rodríguez, DNP, APN, AOCN
Director, Outreach, Prevention and Survivorship
MD Anderson Cancer Center at Cooper
After completing the CME activity, learners should be better able to:
- Evaluate the role that human epidermal growth factor receptor plays in the tumorigenesis and prognosis of patients with HER2-positive solid tumors
- Summarize the efficacy and safety data of both HER2-targeted ADCs and kinase inhibitors in the 2nd line treatment of patients with HER2-positive solid tumors
- Discuss best practices for the safe intravenous administration of ADC therapy and monitoring for adverse events in patients with HER2-positive advanced disease beyond the first-line
- Appreciate the essential role the oncology nurse plays in patient education and management of treatment-related adverse events of HER2-directed therapy
The primary audience for this educational activity is oncology nurses. The secondary target audience consists of other primary care HCPs (e.g., nurse practitioner, pharmacist, physician assistant) involved in the management of patients with gastric cancer, breast cancer and other HER2-positive advanced tumors.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in caring for patients with gastric cancer, breast cancer and other HER2-positive advanced tumors.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.5 contact hour of continuing nursing education of RNs and APNs.
ONCC RECERTIFICATION POINTS
The program content has been reviewed by Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at email@example.com